News

01.10.25

Press Release

Achieve Life Sciences Appoints Dr. Kristen Slaoui and Nancy Phelan to its Board of Directors

New Directors Bring Extensive Leadership Experience in Corporate Strategy and Commercialization SEATTLE and VANCOUVER, British Columbia – January 10, 2025 – Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company focused on the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced that Kristen Slaoui, Ph.D., and Nancy Phelan…

/Read More

01.07.25

Press Release

Achieve Life Sciences Announces Critical Milestone Successfully Reached in ORCA-OL Cytisinicline Clinical Trial Required for NDA Submission

Over 300 Participants Have Completed Cumulative Six Months of Cytisinicline Treatment in the ORCA-OL Trial, Completing the Long-Term Exposure Requirement for NDA Submission  ORCA-OL Long-Term Exposure Timelines Remain on Track with No Safety Concerns Identified  Planned Cytisinicline NDA Submission on Target for Q2 2025 SEATTLE and VANCOUVER, British Columbia – January 7, 2025 Achieve Life…

/Read More

01.06.25

Press Release

Achieve Life Sciences to Host Meetings During the J.P. Morgan Healthcare Conference Week

SEATTLE and VANCOUVER, British Columbia – January 6, 2025 – Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company focused on the development and commercialization of cytisinicline for nicotine dependence, announced today that the company will be hosting in-person one-on-one meetings coinciding with the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, January…

/Read More

12.09.24

Press Release

Achieve Life Sciences Appoints Mark Oki as Chief Financial Officer

SEATTLE and VANCOUVER, British Columbia, December 9, 2024 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company dedicated to the global development and commercialization of cytisinicline for the treatment of nicotine dependence, today announced that Mark Oki has joined the company as its Chief Financial Officer, effective December 5, 2024. Mr….

/Read More

12.03.24

Press Release

Achieve Life Sciences to Advance First Vaping Cessation Therapy After Successful End-of-Phase 2 Meeting with FDA

Milestone Reinforces the Potential for Cytisinicline as a First-in-Class Treatment for Vaping Cessation SEATTLE and VANCOUVER, British Columbia – December 3, 2024 – Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company focused on the development and commercialization of cytisinicline for nicotine dependence, announced today the successful outcome of its End-of-Phase 2 meeting with…

/Read More